An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) will provide a business update and report its first quarter 2024 financial results on May 8, 2024. The company focuses on developing therapeutics to treat seizure disorders.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) fornirà un aggiornamento aziendale e presenterà i risultati finanziari del primo trimestre 2024 l'8 maggio 2024. L'azienda si concentra sullo sviluppo di terapie per trattare i disturbi convulsivi.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) proporcionará una actualización empresarial y reportará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. La compañía se enfoca en desarrollar terapéuticas para tratar los trastornos convulsivos.
Marinus Pharmaceuticals, Inc. (나스닥: MRNS)은 2024년 5월 8일에 사업 업데이트를 제공하고 2024년도 1분기 재무 결과를 보고할 예정입니다. 이 회사는 발작 장애를 치료하기 위한 치료제 개발에 중점을 두고 있습니다.
Marinus Pharmaceuticals, Inc. (Nasdaq : MRNS) fournira une mise à jour des activités et rapportera ses résultats financiers du premier trimestre 2024 le 8 mai 2024. L'entreprise se concentre sur le développement de thérapeutiques pour traiter les troubles convulsifs.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) wird am 8. Mai 2024 ein Geschäftsupdate geben und die Finanzergebnisse für das erste Quartal 2024 vorlegen. Das Unternehmen konzentriert sich auf die Entwicklung von Therapeutika zur Behandlung von Anfallsleiden.
Positive
None.
Negative
None.
RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.
Company
Investors and Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When will Marinus Pharmaceuticals report its first quarter 2024 financial results?
Marinus Pharmaceuticals will report its first quarter 2024 financial results on May 8, 2024.
What is the focus of Marinus Pharmaceuticals?
Marinus Pharmaceuticals focuses on developing innovative therapeutics to treat seizure disorders.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
